Why ResMed's Rally Is Just Getting Started - Seeking Alpha
网页3 天之前 · The good news for ResMed is that GLP-1 drugs are no risk. Even better, ResMed's products improve patient outcomes! According to the company, which cites a SURMOUNT-OSA study, patients with GLP-1 ...
ResMed Inc. (RMD) Latest Stock News & Headlines - Yahoo …
网页Get the latest ResMed Inc. (RMD) stock news and headlines to help you in your trading and investing decisions.
ResMed Adopts New Operating Model to Accelerate Long-term …
网页SAN DIEGO, November 9, 2023 – ResMed (NYSE: RMD, ASX: RMD) today announced a new operating model to accelerate long-term growth. The new operating model introduces dedicated leadership in Product, Revenue, and Marketing to the global executive team.
US FDA Identifies Recall of ResMed's Respiratory Devices as Most …
网页2024年1月11日 · (Reuters) - The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks made by ResMed as most serious as their use could cause major injuries or...
Newsroom | Resmed Inc
网页2024年8月1日 · At ResMed we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases.
Resmed Stock Poised for Growth: Buy Rating Affirmed Amid …
网页2024年4月17日 · In a report released today, Lyanne Harrison from Bank of America Securities reiterated a Buy rating on Resmed (RMD – Research Report), with a price target of $220.00.
ResMed Inc. Announces Results for the Second Quarter of Fiscal …
网页SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2022. Second Quarter 2023 Highlights. All comparisons are...
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal …
网页SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2024. Fourth Quarter 2024 Highlights. All comparisons are to the prior year period. Revenue increased by 9% to $1.2 billion; up 10% on a constant currency basis.
ResMed Faces Market Disruption and Limited Growth: A Sell …
网页3 天之前 · Sep. 18, 2024, 02:46 AM. Wolfe Research analyst Michael Polark downgraded the rating on Resmed (RMD – Research Report) to a Sell yesterday, setting a price target of $180.00. Michael Polark has ...
ResMed Inc. (RMD)
网页2024年8月1日 · At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices…